Phase III study of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1-mutated AML

http://isrctn.com/ 2026 Dataset

View at publisher
Authors: Syndax Pharmaceuticals, David Christopher Taussig
DOI: 10.1186/isrctn42617850
Cited by: 0

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Chromatin Remodeling and Cancer

Publication details

Journal / source
http://isrctn.com/
Publication date
6 February 2026
Document type
Dataset